The use of optogenetics to alter behavior in primates has been challenging, but now a group has managed to activate neurons in the monkey frontal cortex with light and show that this speeds up their performance.
Matthew W. Self 1 and Pieter R. Roelfsema 1, 2, 3 A key problem in our attempts to unravel the neural circuitry that controls behavior has been the lack of tools to control neuronal activity at the millisecond timescale. Optogenetic approaches, in which neurons express light-activated ion-channels so that their activity can be controlled with light have therefore created a great deal of excitement. Optogenetics can target specific, genetically defined groups of neurons, allowing a much finer level of control of their activity than was previously possible. As they report in this issue of Current Biology, Gerits et al. [1] have now managed to show that optogenetics can be used to change behavior in non-human primates.
The use of optogenetics in rodents has developed rapidly over the last few years, providing many new insights into brain function that could not have been obtained otherwise [2, 3] ; indeed, the editors of Science went so far as to declare in 2010 that optogenetics was one of the ''breakthroughs of the decade''. Applying optogenetic techniques to the primate brain is particularly exciting, as it raises the prospect of being able experimentally to control complex behaviors that can only be studied in monkeys. Optogenetics in monkeys could be used to study, for example, the contribution of specific types of neurons to consciousness, shifts of attention, working memory or mirror neuron activity. At the same time, optogenetics in monkeys is of crucial importance for bridging the gap between the work in rodents and the design of new therapies for human patients with neurological and psychiatric diseases.
Optogenetics in primates is more challenging than in rodents, because many of the genetic tricks that have been developed for mice, like the production of transgenic animals, are not available for primates. A few studies have applied optogenetic methods in awake-behaving monkeys, and they have demonstrated well controlled changes in neuronal activity [4] [5] [6] . But these studies have not previously reported behavioral effects and, despite anecdotal reports of attempts by other groups, the control of behavior with optogenetic stimulation had yet to be demonstrated. This lack of behavioral effects in monkeys was puzzling, as optogenetic stimulation is now routinely used to alter behavior in rodents. In rodents, it is even possible to produce behavioral effects by the stimulation of a single brain cell [7] . Why has it been so difficult to produce behavioral effects in monkeys? Does the larger brain volume of primates mean that more tissue needs to be stimulated, are there compensatory mechanisms reducing the impact of optical stimulation, or have the behavioral tests applied in the optogenetic studies in monkeys so far not been sensitive enough [8] ?
Although it is not entirely clear which factor was responsible for the failure of previous attempts, Gerits et al. [1] have been able to meet the challenge. They expressed the light-gated protein channelrhodopsin-2 (ChR2) in neurons in the frontal eye fields of monkeys by injecting an AAV5 viral vector at multiple sites in the arcuate sulcus. The frontal eye fields are a region of frontal cortex involved in the generation of eye movements. Crucially, the authors first mapped the brain regions activated by an eye movement task with fMRI in the monkeys; they then specifically injected the virus in sites involved in the task. Once sufficient time had elapsed for the cells to express ChR2 protein, the neurons at these sites could be activated with blue light via two implanted optical fibers ( Figure 1 ).
Gerits et al. [1] verified that the optogenetic stimulation was indeed effective by fMRI, which was used to map out the circuits whose activity level was directly or trans-synaptically influenced by the light pulses. Most importantly, the authors observed a clear effect of the light pulses on the behavior of the monkeys. On the trials where optogenetic stimulation was applied, the monkeys' reaction time in the eye movement task was speeded by approximately 20 milliseconds ( Figure 1 ). This exciting effect heralds the beginning of optical control of behavior in primates and future studies will undoubtedly refine this technique using more specific stimulation parameters -for example, stimulating at specific points during the task,or targeting specific neural populations.
In addition to the control of complex behavior, the development of optogenetics in monkeys will have many exciting applications. Gerits et al. [1] show that fMRI can be used to pinpoint the neural circuits whose activity is altered by stimulating the arcuate sulcus (Figure 2 ). We know that performance in cognitive tasks relies on the coordinated activity of many groups of neurons in cortical and subcortical brain regions. This is even true for simple tasks, where monkeys are instructed to make an eye movement to one of a few potential targets. We still do not understand well how cells in different brain areas work together to implement a cognitive program.
The combination of optogenetics with fMRI is a particularly powerful tool for studying the effect of a perturbation of activity in one brain region on the activity in other brain regions at the whole brain level. It promises direct insight into how neurons in different brain areas work together [9] and complements previous approaches that have used electrical microstimulation in combination with single cell recording or fMRI [10] [11] [12] .
One of the advantages of optogenetics is that the light pulses do usually not activate fibers-of-passage. Furthermore, the use of promotors that induce the expression of light-sensitive channels in specific cells types or even specific cortical layers [13] will allow the study of how these cells types or layers contribute to the communication between brain areas. For example, we do not understand well how the effects of feedforward connections that propagate information from lower to higher sensory areas differ from the effect of feedback connections that propagate information in the opposite direction. Feedforward connections are thought to be important for automatic, 'pre-attentive' information processing, whereas feedback connections are thought to control selective attention and consciousness [14, 15] . Optogenetics in monkeys can now be used to dissect these putative functions.
Future studies can also develop the use of optogenetics in monkeys further for new therapies to alleviate the conditions of patients with brain Figure 1 . Optogenetic manipulation of behavior in a monkey. Gerits et al. [1] transduced neurons in the arcuate sulcus, a region of the frontal cortex of monkeys that controls rapid eye movements (saccades), with a virus carrying the gene for channelrhodopsin-2, a light-gated ion channel. The neurons in this region were stimulated with blue light delivered through two implanted optical fibers causing increased activity in these regions and connected areas. The monkeys were trained to fixate on the central red dot and to then make a saccade towards the green target when one of the grey dots was dimmed (the 'Go signal). Stimulating neurons in the arcuate sulcus with light caused a speeding of the reaction times of the monkeys (blue bar) compared to no-stimulation (grey bar). disease. There is a precedent for this approach, because research in non-human primates contributed importantly to the development of deep-brain stimulation for patients with neurological and psychiatric diseases [16] . The cell-type specificity of optogenetics will allow control over more selective subsets of neurons than deep-brain stimulation, thereby providing the potential of more precise therapies that can be targeted to those cells that matter for the disease. The primary cause of hereditary breast and ovarian cancer syndrome is heterozygous germline mutation of the breast cancer early onset genes BRCA1 and BRCA2. Both BRCA gene products are essential for efficient DNA double strand break (DSB) repair mediated by homologous recombination (HR). In addition, BRCA1 acts to integrate the activities of several protein partners during the response to DSBs and contributes to DNA damage-induced checkpoint activation in part through promoting ATR-dependent phosphorylation of checkpoint kinase 1 (CHK1). Within the context of heterozygous BRCA patients, tumors lose the wild-type allele, motivating synthetic lethal therapeutic approaches that exploit the tumor-specific HR deficiency [1] [2] [3] [4] . A fundamental understanding of BRCA-directed DNA repair mechanisms therefore has clear implications for the effective design and implementation of DNA-damaging chemotherapeutics strategies.
The BRCA1 protein is organized into two main functional domains. The amino-terminal region contains a RING domain that imparts E3 ubiquitin ligase activity, and the carboxy-terminal part of the protein contains two BRCT (BRCA1 C-terminal) repeats that bind to a phosphorylated serine present within a consensus SPXF motif in binding partners [5, 6] . Mutations resulting in highly penetrant breast and ovarian cancers affect either of these two domains. Because many pathogenic mutations in the amino-terminal BRCA1 RING domain affect its interaction with the stoichiometric binding partner BARD1, the contributions of BRCA1 E3 ligase activity to DNA damage responses and tumor suppression have until recently remained enigmatic. The advent of genetically engineered cells and mouse models has begun to shed light on this important topic. Ludwig, Baer and colleagues have generated a mouse model in which a single amino acid substitution (I26A) within the RING domain renders BRCA1 E3 ligase inactive by disrupting interaction with E2 enzymes, while leaving intact its ability to heterodimerize with BARD1 [7, 8] . Surprisingly, BRCA1 I26A cells, both in culture and in mice, are not deficient in homology-directed repair of DSBs and do not display sensitivity to DNA inter-strand crosslinking (ICL) agents. Furthermore, BRCA1 I26A mice are not tumor prone. However, knock-in of a cancer-causing BRCA1 RING domain allele, BRCA1 C61G, that disrupts E3 ligase activity and BARD1 interaction does lead to DNA repair deficiency and cancer susceptibility [9] . Collectively, these findings suggest that BRCA1 E3 ligase activity is dispensable for its tumor suppressor and genome integrity functions, while interaction with BARD1 is the more relevant target of pathogenic RING
